Citius Pharmaceuticals Inc CTXR 深 滬
已收盤 07-02 16:00:00 美东时间
0.5746
-0.034
-5.63%
華盛通- 最 高0.63
- 今 開0.618
- 成交量 20.75万股
- 最 低 0.5746
- 昨 收 0.6089
- 總市值 1.58万
- 52周最高 2.19
- 市盈率 靜 --
- 換手率 0.76%
- 52周最低 0.476
- 委 比 0.00%
- 總股本 2.75万
- 歷史最高 137.25
- 量 比 0.98
- 振 幅 9.10%
- 歷史最低 0.476
- 每 手 1
- 風險率 0.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Citius Oncology在ASCO公布LYMPHIR联合帕博利珠单抗治疗妇科肿瘤I期数据
Citius Oncology， Inc．近日在2026年美国临床肿瘤学会年会上，以壁报形式公布了LYMPHIR联合帕博利珠单抗治疗复发或难治性妇科恶性肿瘤...
06-01 22:59
Citius Oncology Presents Phase 1 Clinical Data Of LYMPHIR In Combination With Pembrolizumab In Patients With Recurrent Or Refractory Gynecologic Malignancies At American Society Of Clinical Oncology Annual Meeting
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today highlighted
06-01 19:21
美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
05-19 10:55
HC Wainwright & Co. Assumes Citius Pharmaceuticals at Buy, Announces Price Target of $4
HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy rating and announces Price Target of $4.
05-18 23:06
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 635.6% to $2.0...
05-18 20:05
Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility
Citius Pharmaceuticals ( ($CTXR) ) just unveiled an update. On May 4, 2026, Cit...
05-09 06:05
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch Distribution by regional partners through Named Patient Programs in specific international mark...
04-29 20:00
UPDATE: Reported Earlier, Citius Pharma Prices $5M Offering Of 5,076,143 Shares At A Price Of $0.985/Share
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that
04-24 23:44
What's Behind The Drop In Citius Pharmaceuticals?
Citius Pharmaceuticals (NASDAQ:CTXR) shares tumbled on Friday after it announced a registered direct offering, raising dilution concerns.
04-24 22:47
Citius Pharmaceuticals to raise $5M in equity offering
Citius Pharmaceuticals (CTXR) said it entered a definitive agreement to sell about 5.08M shares of common stock, or pre-funded warrants, at $0.985 per share in a registered direct offering priced at t...
04-24 20:20
